Scopio Labs
Scopio Labs develops Full-Field Digital Cell Morphology imaging platforms and AI-powered decision support software for clinical hematology laboratories, serving hospitals, academic medical centers, and reference laboratories globally through direct sales and channel partnerships with Beckman Coulter Diagnostics and Siemens Healthineers.
- Company typePrivate
- Founded2015
- HeadquartersTel Aviv, Israel
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Scopio Labs does
Scopio Labs Ltd. is an Israeli-headquartered medical technology company founded in 2015 that develops Full-Field Digital Cell Morphology platforms for hematology diagnostics. Its core offering combines proprietary computational photography hardware (X100 and X100HT high-resolution slide scanners that capture entire blood smear and bone marrow aspirate slides at 100x oil-immersion equivalent resolution) with AI-powered decision support software for peripheral blood smear review and bone marrow aspirate analysis. The AI models pre-classify white blood cells into 16+ classes, evaluate red blood cell morphology across 23 parameters, perform platelet estimation, and detect platelet clumps, with clinical validation demonstrating 99.77% agreement with manual microscopy for RBC morphology and 96.29% accuracy for WBC differentials across multicenter studies. The company has accumulated four FDA clearances and two EU IVDR certifications, including a De Novo clearance that established a new regulatory category for digital bone marrow aspirate analysis.
Scopio Labs generates revenue through a hardware-plus-software model: capital sales of X100/X100HT imaging platforms integrated with licensed AI software applications (Full-Field Peripheral Blood Smear Application and Full-Field Bone Marrow Aspirate Application). Distribution is hybrid, combining direct enterprise sales led by a Chief Commercial Officer with global channel partnerships signed with Beckman Coulter Diagnostics (since July 2022) and Siemens Healthineers (since May 2023), both subsequently expanded to cover the bone marrow aspirate product line. The company serves clinical hematology laboratories, multi-site hospital networks, academic medical centers, and specialized hematopathology departments across the United States, United Kingdom, continental Europe, and Israel, with named customers including Mount Sinai, PathGroup, Tel Aviv Sourasky Medical Center, Ghent University Hospital, and SYNLAB-affiliated reference laboratories. A Complete Blood Morphology analyzer offering fully autonomous morphology analysis is in development. The company also operates a parallel veterinary sub-brand, ScopioVet, in the US, UK, and Ireland.
Scopio Labs firmographics
Firmographics- Name
- Scopio Labs
- Legal name
- Scopio Labs Ltd.
- Website
- https://scopiolabs.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Scopio Labs develops Full-Field Digital Cell Morphology imaging platforms and AI-powered decision support software for clinical hematology laboratories, serving hospitals, academic medical centers, and reference laboratories globally through direct sales and channel partnerships with Beckman Coulter Diagnostics and Siemens Healthineers.
- Ownership category
- akta.pro rank
Scopio Labs industry classification
Industry- Product category
- Digital Hematology Imaging Systems
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826), Optical Instruments & Lenses (3827)
- akta.pro primary industry
- Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Anatomic Pathology LIS & Digital Pathology Workflow (HLACAMAB)
Keywords
Where Scopio Labs is headquartered
LocationHeadquarters
- HQ city
- Tel Aviv
- HQ country
- Israel
- HQ region
- Middle East
Offices3 records
Markets served
Scopio Labs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D
Revenue model
- Digital Morphology Platforms (Hardware + Software): Sale of X100 and X100HT digital slide-scanning devices integrated with AI-powered software applications for peripheral blood smear and bone marrow aspirate analysis. Platforms are sold to hematology labs, hospitals, and laboratory networks globally through direct sales and channel partners.
- Software Applications (Subscriptions/Licensing): AI-powered decision support software applications (Full-Field Peripheral Blood Smear Application, Full-Field Bone Marrow Aspirate Application) licensed for use on Scopio's X100/X100HT platforms. CBM analyzer under development. Revenue generated through software licensing and application fees integrated with hardware platform sales.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | X100 and X100HT platforms with integrated software applications |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels9 records
Scopio Labs product offering
Product offeringCore offering
Scopio Labs develops and sells Full-Field Digital Cell Morphology imaging platforms (X100 and X100HT) that capture entire peripheral blood smear and bone marrow aspirate slides at 100x magnification. The hardware platforms run AI-powered applications including the Full-Field Peripheral Blood Smear Application, Full-Field Bone Marrow Aspirate Application, and the in-development Complete Blood Morphology (CBM) analyzer that provide automated cell classification, morphological analysis, and remote review for clinical hematology laboratories.
Product overview
Scopio Labs offers a platform-based architecture centered on the X100 and X100HT Full-Field Digital Cell Morphology imaging platforms, which serve as the hardware foundation for a suite of AI-powered applications. The core applications include the Full-Field Peripheral Blood Smear Application (FDA-cleared and CE-marked) for digital PBS review with WBC differential, RBC morphology, and platelet estimation, and the Full-Field Bone Marrow Aspirate Application (CE-marked, FDA De Novo cleared) for comprehensive bone marrow analysis. The Complete Blood Morphology (CBM) Analyzer, currently under development, represents the next-generation autonomous morphology solution built on the same Full-Field technology platform, designed to deliver fully automated results from scan to final report.
Differentiator
Problem solved
Functional benefit
Brands
- ScopioVet: Digital cytology system for veterinary professionals, offered in the United States, United Kingdom and Ireland.
Products and services
- X100 and X100HT Full-Field Digital Cell Morphology Imaging Platforms Hardware imaging platforms that capture full-field digital images of peripheral blood smears and bone marrow aspirates at 100x magnification resolution. The X100 processes up to 15 samples/hour with a 3-slide tray; the X100HT processes up to 40 samples/hour with 30-slide capacity. Both feature computational photography for high-resolution imaging and embedded AI decision support, sold to clinical hematology laboratories and hospital networks globally.
- Full-Field Peripheral Blood Smear (FF-PBS) Application FDA-cleared and CE-marked software application for digital peripheral blood smear review. Features adaptive monolayer identification, WBC pre-classification into 16 classes, RBC morphology evaluation across 23 parameters, and platelet estimation with clump detection. Reduces PBS review turnaround time by 60% and enables remote review over secure hospital networks.
- Full-Field Bone Marrow Aspirate (FF-BMA) Application World's first complete digital workflow for bone marrow aspirate scanning and analysis. CE-marked and FDA De Novo cleared. Combines high-resolution Full-Field imaging with AI-powered decision support for blast cell estimation, plasma cell estimation, M:E ratio calculation, and bone marrow smear quality assessment, enabling remote review of entire smears at 100x.
- Complete Blood Morphology (CBM) Analyzer Next-generation autonomous blood morphology analyzer that fully automates peripheral blood smear analysis from scan to final report. Built on Scopio's proprietary Full-Field technology platform with advanced computational imaging and deep learning AI. Analyzes thousands of cells (10x more than the 100-200 cell manual standard of care) for fully autonomous, standardized morphology analysis.
Quantifiable outcome
- 60% reduction in peripheral blood smear review turnaround time
- +9 more outcomes
Companies that use Scopio Labs
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Scopio Labs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability7 records
Feature7 records
Scopio Labs partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Siemens HealthineerscoreGlobal distribution agreement signed May 2023 granting Siemens Healthineers rights to distribute Scopio's X100 and X100HT digital morphology platforms with Full-Field Peripheral Blood Smear Application, complementing Siemens Healthineers' existing hematology portfolio including Atellica HEMA 570/580 Analyzers. Expanded in January 2025 to include FF-BMA Application globally. Partnership supports Siemens Healthineers' goal of providing automated and digitized solutions for hematology workflow transformation.
- Beckman Coulter DiagnosticscoreWorldwide partnership since July 2022 to accelerate adoption of Scopio's next-generation peripheral blood smear platforms. Expanded in September 2024 to include global distribution of the Full-Field Bone Marrow Aspirate (FF-BMA) Application. Beckman Coulter, part of Danaher Corporation (NYSE: DHR), is a global leader in clinical diagnostics with 80+ years of experience. In 2023, Beckman Coulter announced an end-to-end automated hematology solution connecting its DxH 900 Workcell and DxH Slidemaker Stainer II with the Scopio X100HT high-throughput digital cell morphology platform.
Scale indicators16 records
Recent moves6 records
Expansion highlights6 records
Scopio Labs competitors and assessment
Company assessmentBroad incumbents
- Sysmex: Global leader in hematology analyzers and the dominant supplier of CBC/diff instrumentation; competes with Scopio's morphology workflow through integrated automated digital cell imaging (DI-60) and is the most direct incumbent competitor in clinical hematology labs.
- Beckman Coulter Diagnostics (Danaher): Major hematology analyzer vendor and Scopio's global distribution partner; offers DxH series analyzers plus its own DxH Slidemaker Stainer II integrated with Scopio X100HT, making it both a critical channel and a strategic incumbent that could internalize morphology.
- Siemens Healthineers: Global diagnostics company distributing the Atellica HEMA 570/580 analyzers and Scopio's X100/X100HT; as a partner and broader hematology incumbent, it is both the route to market and a potential competitor with internal morphology ambitions.
- Roche Diagnostics: Major clinical diagnostics incumbent with hematology and digital pathology offerings; competes for hospital lab budgets that Scopio targets and is a likely reference point for hospital procurement evaluations.
- Mindray: Large Chinese-origin medical device company with a growing hematology analyzer portfolio; competes on price-sensitive hematology lab deals globally and is a credible alternative for cost-conscious hospital networks.
- HORIBA Medical: Hematology and clinical chemistry analyzer vendor with growing digital morphology ambitions; competes for the same mid-sized hospital and reference lab morphology budgets as Scopio.
Direct peers
- CellaVision: Swedish-based digital morphology company providing automated WBC differential and RBC morphology on digital slide images; offers the most directly overlapping digital cell morphology product to Scopio's X100/X100HT and is the closest direct peer in hematology lab digitization.
Emerging players
- Mikroscan Technologies: Emerging digital pathology vendor offering whole-slide imaging systems for remote review; partial overlap with Scopio's digital slide imaging and remote consultation value proposition in smaller hospital settings.
- OptraScan: Digital pathology scanning vendor expanding into hematology and remote review use cases; adjacent competitor targeting budget-constrained hospital digital pathology deployments.
Others
- Hologic: Diagnostic and women's health company with a clinical diagnostics franchise that occasionally overlaps with cytology/hematology workflows; relevant adjacent peer for hospital capital allocation decisions.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Scopio Labs social profiles
Digital presenceScopio Labs compliance and trust
Trust signalCompliance7 records
Scopio Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Scopio Labs leadership team
Management profileNumber of profiles
Profiles9 records
Scopio Labs funding detail
Funding detailFunding overview
Funding rounds8 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Scopio Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Scopio Labs
What does Scopio Labs do?
Scopio Labs develops and sells Full-Field Digital Cell Morphology imaging platforms (X100 and X100HT) that capture entire peripheral blood smear and bone marrow aspirate slides at 100x magnification. The hardware platforms run AI-powered applications including the Full-Field Peripheral Blood Smear Application, Full-Field Bone Marrow Aspirate Application, and the in-development Complete Blood Morphology (CBM) analyzer that provide automated cell classification, morphological analysis, and remote review for clinical hematology laboratories.
Is Scopio Labs a public or private company?
Scopio Labs is a private company. It is classified as venture growth investor backed and is currently operating.
When was Scopio Labs founded?
Scopio Labs was founded in 2015. It employs 51 to 100 people.
Where is Scopio Labs based?
Scopio Labs is headquartered in Tel Aviv, Israel, in the Middle East region.
How does Scopio Labs make money?
Two revenue lines are on record. Digital Morphology Platforms (Hardware + Software) is the primary driver. The others are software Applications (Subscriptions/Licensing).
Who are Scopio Labs's main competitors?
Broad incumbents on record are Sysmex, Beckman Coulter Diagnostics (Danaher), Siemens Healthineers, Roche Diagnostics, Mindray and HORIBA Medical. CellaVision is listed as a direct peer. Emerging players are Mikroscan Technologies and OptraScan. Hologic is listed as an others.
Does Scopio Labs have an API?
No public API is recorded for Scopio Labs.
What industry is Scopio Labs in?
Scopio Labs's product category is Digital Hematology Imaging Systems. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 334516 and its SIC code is 3826.